Claims
- 1. A compound of Formula I
- 2. A compound of Formula II
- 3. The compound of claim 1 wherein R1 and R2 are methyl.
- 4. The compound of claim 1 wherein X is OH.
- 5. The compound of claim 1 wherein X is NHOH.
- 6. The compound of claim 1 wherein R3 is bromo or iodo.
- 7. The compound of claim 1 wherein R4 is hydrogen.
- 8. The compound of claim 1 wherein n is 1.
- 9. A compound selected from:
(S)-4-(4′-Bromo-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-4-(4′-Bromo-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid hydroxyamide; (S)-4-(4′-Bromo-biphenyl-4-sulfonyl)-2,2-dimethyl-1,1-dioxo-thiomorpholine-3-carboxylic acid; (S)-4-(4′-Bromo-biphenyl-4-sulfonyl)-2,2-dimethyl-1,1-dioxo-thiomorpholine-3-carboxylic acid hydroxyamide; (S)-4-(4′-Hydroxymethyl-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-4-(2′-Carboxy-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-4-(4′-Methanesulfonyl-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-4-(4′-Formyl-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-4-(3′-Formyl-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-4-(4′-Dimethylamino-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-4-(2′-Bromo-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-4-{4′-[(2-Hydroxy-ethylamino)-methyl]-biphenyl-4-sulfonyl}-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-4-{4′-[(Diisopropylamino)-methyl]-biphenyl-4-sulfonyl}-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-4-[4′-(Isobutylamino-methyl)-biphenyl-4-sulfonyl]-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-2,2-Dimethyl-4-(4′-pyrrolidin-1-ylmethyl-biphenyl-4-sulfonyl)-thiomorpholine-3-carboxylic acid; (S)-4-(4′-Cyclohexylaminomethyl-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-2,2-Dimethyl-4-(4′-thiomorpholin-4-ylmethyl-biphenyl-4-sulfonyl)-thiomorpholine-3-carboxylic acid; (S)-4-(4′-Hydroxymethyl-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid hydroxyamide; (S)-4-(3′-Amino-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid hydroxyamide; (S)-4-(4′-Dimethylamino-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid hydroxyamide; (S)-4-(3′-Bromo-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid hydroxyamide; (S)-2,2-Dimethyl-4-(4′-piperidin-1-ylmethyl-biphenyl-4-sulfonyl)-thiomorpholine-3-carboxylic acid hydroxyamide; (S)-4-{4′-[(Benzyl-isopropyl-amino)-methyl]-biphenyl-4-sulfonyl}-2,2-dimethyl-thiomorpholine-3-carboxylic acid hydroxyamide; (S)-2,2-Dimethyl-4-[4′-(4-methyl-piperazin-1-ylmethyl)-biphenyl-4-sulfonyl]-thiomorpholine-3-carboxylic acid hydroxyamide; (S)-2,2-Dimethyl-4-(4′-piperidin-1-ylmethyl-biphenyl-4-sulfonyl)-thiomorpholine-3-carboxylic acid hydroxyamide; (S)-4-(4′-Bromo-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-2,2-Dimethyl-4-(3′-nitro-biphenyl-4-sulfonyl)-thiomorpholine-3-carboxylic acid; (S)-2,2-Dimethyl-4-(4-naphthalen-1-yl-benzenesulfonyl)-thiomorpholine-3-carboxylic acid; (S)-4-(4′-Chloro-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-4-(4′-Formyl-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-2,2-Dimethyl-4-(3′-methyl-biphenyl-4-sulfonyl)-thiomorpholine-3-carboxylic acid; (S)-4-(4′-Fluoro-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-4-(4-1 ,3-Benzodioxol-5-yl-benzenesulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-4-(3′-Chloro-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-4-(3′-Formyl-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-2,2-Dimethyl-4-(4-naphthalen-2-yl-benzenesulfonyl)-thiomorpholine-3-carboxylic acid; (S)-2,2-Dimethyl-4-(4′-methylsulfanyl-biphenyl-4-sulfonyl)-thiomorpholine-3-carboxylic acid; (S)-2,2-Dimethyl-4-([1,1′;4′,1″]terphenyl-4-sulfonyl)-thiomorpholine-3-carboxylic acid; (S)-4-(2′,4′-Difluoro-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-2,2-Dimethyl-4-(4′-phenoxy-biphenyl-4-sulfonyl)-thiomorpholine-3-carboxylic acid; (S)-4-(3′,4′-Difluoro-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-4-(3′-Chloro-4′-fluoro-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-4-(4′-Ethoxy-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-4-(4′-Isopropyl-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-2,2-Dimethyl-4-(4′-trifluoromethoxy-biphenyl-4-sulfonyl)-thiomorpholine-3-carboxylic acid; (S)-4-(4′-Hydroxymethyl-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-4-(4′-Ethyl-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-4-(3′-Formyl-4′-methoxy-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-4-(4′-tert-Butyl-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-4-(4′-Fluoro-3′-methyl-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-4-(2′-Fluoro-[1,1′;4′,1″]terphenyl4″-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-4-(4′-Dimethylamino-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-2,2-Dimethyl-4-(3′,4′,5′-trimethoxy-biphenyl-4-sulfonyl)-thiomorpholine-3-carboxylic acid; (S)-4-(2′,4′-Dichloro-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-2,2-Dimethyl-4-(4′-trifluoromethyl-biphenyl-4-sulfonyl)-thiomorpholine-3-carboxylic acid; (S)-4-(3′-Fluoro-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-2,2-Dimethyl-4-(3′-trifluoromethoxy-biphenyl-4-sulfonyl)-thiomorpholine-3-carboxylic acid; (S)-4-(2′,6′-Dimethoxy-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-4-(3′-Acetyl-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-4-(3′-Cyano-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-4-(2′-Formyl-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; (S)-4-(2′-Fluoro-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid; and (S)-4-(3′-Bromo-biphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid.
- 10. A compound of Formula III
- 11. A compound of Formula IV
- 12. The compound of claim 10 wherein R1 and R2 are methyl.
- 13. The compound of claim 10 wherein X is OH.
- 14. The compound of claim 10 wherein X is NHOH.
- 15. The compound of claim 10 wherein R3 is chloro or methyl.
- 16. The compound of claim 10 wherein R4 is hydrogen.
- 17. The compound of claim 10 wherein n is 1.
- 18. A compound selected from:
(S)-4-[4-(5-Chloro-thiophen-2-yl)-benzenesulfonyl]-2,2-dimethyl-thiomorpholine-3-carboxylic acid; and (S)-2,2-Dimethyl-4-[4-(5-methyl-thiophen-2-yl)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid.
- 19. A pharmaceutical composition, comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable carrier, diluent, or excipient.
- 20. A pharmaceutical composition, comprising a compound according to claim 2, or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable carrier, diluent, or excipient.
- 21. A pharmaceutical composition, comprising a compound according to claim 10, or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable carrier, diluent, or excipient.
- 22. A pharmaceutical composition, comprising a compound according to claim 11, or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable carrier, diluent, or excipient.
- 23. A method for inhibiting an MMP enzyme in an animal, comprising administering to the animal an MMP enzyme inhibiting amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable carrier, diluent, or excipient.
- 24. A method for inhibiting an MMP enzyme in an animal, comprising administering to the animal an MMP enzyme inhibiting amount of a compound according to claim 10, or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable carrier, diluent, or excipient.
- 25. A method for treating a cancer, comprising administering to a mammal in need of treatment an anticancer effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.
- 26. A method for treating breast carcinoma, comprising administering to a mammal in need of treatment an anticancer effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.
- 27. A method for treating a heart failure, comprising administering to a mammal in need of treatment an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.
- 28. A method for treating a inflammation, comprising administering to a mammal in need of treatment an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.
- 29. A method for treating a rheumatoid arthritis, comprising administering to a mammal in need of treatment an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.
- 30. A method for treating a osteoarthritis, comprising administering to a mammal in need of treatment an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.
- 31. A method for treating a cancer, comprising administering to a mammal in need of treatment an anticancer effective amount of a compound of claim 10, or a pharmaceutically acceptable salt thereof.
- 32. A method for treating breast carcinoma, comprising administering to a mammal in need of treatment an anticancer effective amount of a compound of claim 10, or a pharmaceutically acceptable salt thereof.
- 33. A method for treating a heart failure, comprising administering to a mammal in need of treatment an effective amount of a compound of claim 10, or a pharmaceutically acceptable salt thereof.
- 34. A method for treating a inflammation, comprising administering to a mammal in need of treatment an effective amount of a compound of claim 10, or a pharmaceutically acceptable salt thereof.
- 35. A method for treating a rheumatoid arthritis, comprising administering to a mammal in need of treatment an effective amount of a compound of claim 10, or a pharmaceutically acceptable salt thereof.
- 36. A method for treating a osteoarthritis, comprising administering to a mammal in need of treatment an effective amount of a compound of claim 10, or a pharmaceutically acceptable salt thereof.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims benefit of priority from U.S. provisional patent application No. 60/268,755, filed Feb. 14, 2001.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60268755 |
Feb 2001 |
US |